T. Rowe Price Associates
PRNB

T. Rowe Price Associates’s Principia Biopharma Inc. Common Stock PRNB Stock Holding History

T. Rowe Price Associates’s Portfolio PRNB Stock Details PRNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,907,436
Closed -$114M – 2653
2020
Q2 		$114M Buy
1,907,436
+100,008
+6% +$6.18M 0.01% 599
2020
Q1 		$107M Buy
1,807,428
+251,656
+16% +$14.7M 0.02% 555
2019
Q4 		$85.2M Buy
1,555,772
+639,994
+70% +$23.9M 0.01% 714
2019
Q3 		$25.9M Sell
915,778
-7,174
-0.8% -$263K ﹤0.01% 1079
2019
Q2 		$30.6M Buy
922,952
+8,970
+1% +$280K ﹤0.01% 1039
2019
Q1 		$31.1M Buy
913,982
+2,010
+0.2% +$63.9K ﹤0.01% 1033
2018
Q4 		$25M Buy
911,972
+44,913
+5% +$1.16M ﹤0.01% 1076
2018
Q3 		$25.3M Buy
+867,059
New +$24.5M ﹤0.01% 1142

Other funds holding PRNB

Ohio Public Employees Retirement System (OPERS)
Ohio Public Employees Retirement System (OPERS) Columbus, Ohio $34B AUM 40.73% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return
Skandinaviska Enskilda Banken (SEB)
Skandinaviska Enskilda Banken (SEB) Stockholm, Sweden $2.66B AUM 26.2% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Public Employees Retirement Association of Colorado
Public Employees Retirement Association of Colorado Denver, Colorado $28.9B AUM 44.1% 1-Year Est. Return
AB
Amalgamated Bank New York $14.5B AUM 44.3% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
ADL
Asset Dedication LLC San Francisco, California $1.59B AUM 26.56% 1-Year Est. Return

T. Rowe Price Associates's PRNB Position: Q3 2020 in Review

T. Rowe Price Associates sold out of Principia Biopharma Inc. Common Stock (PRNB) in Q3 2020, closing a stake of 1,907,436 shares — an estimated $114M sold.

T. Rowe Price Associates first reported a position in PRNB in Q3 2018 and held it in 8 quarters. The position peaked at $114M in Q2 2020. 9 funds tracked by Wall St. Rank hold PRNB as of Q3 2020.

  • T. Rowe Price Associates reported no remaining Principia Biopharma Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • T. Rowe Price Associates sold 1,907,436 Principia Biopharma Inc. Common Stock shares in Q3 2020, an estimated $114M.
  • T. Rowe Price Associates first reported a position in Principia Biopharma Inc. Common Stock in Q3 2018 and held it in 8 quarters.
  • T. Rowe Price Associates's Principia Biopharma Inc. Common Stock position peaked at $114M in Q2 2020.
  • 9 funds tracked by Wall St. Rank held Principia Biopharma Inc. Common Stock as of Q3 2020.

Based on T. Rowe Price Associates's 13F filing for Q3 2020, filed 16 Nov 2020.